How I Do My Research
I focus on four main biotech companies: Vertex Pharmaceuticals (VRTX), Moderna (MRNA), Recursion Pharmaceuticals (RXRX), and Beam Therapeutics (BEAM). I use the same process for each one so my views stay consistent and fair.
Who They Are
Science & Data
Real-World Impact
Opportunities
Risks
1.
Start With Who They Are
For every company, I first look at:
• Their mission and what problems they want to solve
• The diseases or areas they focus on
• The main treatments or tools they already have approved
• The most important programs still in development
This gives me a clear picture of what they stand for and who they are trying to help.
2.
Follow the Science and Clinical Data
Next, I dig into the medical side:
• Recent clinical trial results and study readouts
• FDA approvals, rejections, or safety updates
• New research findings that change how we think about a disease
• Partnerships and collaborations with other companies, labs, or hospitals
Here I’m asking: is this company actually moving medicine forward in a meaningful way?
3.
Look at Real World Impact
I then think about how their work could show up in real life:
• How early their tools can catch disease
• How much their treatments might improve quality of life
• Whether they can reach patients who don’t have many options today
• How their approach is different from what already exists
This step connects the science to patients and doctors, not just charts and numbers.
4.
5.
Map Out the Main Opportunities
For each company, I write down:
• Which programs in the pipeline look most promising
• Which big unmet medical needs they are targeting
• Any clear strengths they have (platform, data, technology, or team)
• How their work could change care if it succeeds
This is my “what could go right for patients and the field” list.
Map Out the Main Risks
I also keep a matching “what could go wrong” list:
• Trials that might fail or are already struggling
• Safety signals or side effects that could limit use
• Strong competing approaches from other companies or labs
• Over reliance on a single idea, target, or platform
This keeps my view balanced and stops me from getting carried away by hype.
6. Compare the Four Companies
Once I’ve done this for all four, I compare them on:
- How innovative their science is
- How strong and diverse their pipeline looks
- How much risk is tied to each key program
- How likely they are to shape the future of care in their area
This helps me see which companies feel more steady and which are more experimental.
7. Make a Clear Personal View
At the end, I turn everything into a simple call for each company:
- The developments that stood out the most
- The biggest open questions or concerns
- Whether my view is Bullish, Neutral, or Bearish
- The key events I’m watching next (trial readouts, FDA decisions, major data releases, etc.)
I update this work about every two weeks, or sooner if there is major news or new data.
8. Where I Get My Information
IR
SEC
FDA
NWS
Company investor relations pages (for official updates)
SEC filings (for detailed reports)
FDA announcements and ClinicalTrials.gov
Earnings calls, news sites, and healthcare platforms
9. How I Share It
I publish finding in a simple, repeatable layout:
✓ Company Summary
✓ Pipeline Updates
✓ Recent News
✓ Opportunities
✓ Medical Impact
✓ Personal Analysis
✓ Risks
✓ Sources